阿维A市场 - 按产品类型（品牌、仿製药）、剂量强度（10毫克、25毫克、50毫克）、应用（牛皮癣、鱼鳞病、毛囊病）、配销通路（医院药房、零售药房）、最终用途- 全球预测（2024 - 2032）

Acitretin Market - By Product Type (Branded, Generics), Dosage Strength (10 mg, 25 mg, 50 mg), Application (Psoriasis, Ichthyosis, Darier Disease), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), End-use - Global Forecast (2024 - 2032)

出版日期: 2024年04月26日 | 出版商:

Global Market Insights Inc. | 英文 230 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在蓬勃发展的製药和医疗保健基础设施的支持下，全球阿维A市场2024年至2032年的复合年增长率将超过4.6%。据投资印度报告称，印度製药业到2024年将达到650亿美元，到2030年将翻一番，达到1300亿美元。和卡介苗疫苗需求，以及90%的需求。阿维A在治疗严重干癣方面的临床有效性和安全性已得到证实，因此在临床实践中已广泛采用。

医疗保健提供者更喜欢能够提供可靠结果且副作用最小的治疗方法，因此阿维A成为首选。它在控制牛皮癣症状（如鳞屑、发炎和斑块形成）方面的功效可提高患者的满意度和依从性。此外，药物的安全性支持长期使用，进一步增强了其对临床医生的吸引力。

整个阿维A产业根据产品类型、剂量强度、应用、配销通路、最终用途和地区进行分类。

仿製药领域将在预测期内实现显着的复合年增长率。阿维A的仿製药为品牌药物提供了具有成本效益的替代品，使更广泛的患者群体更容易获得治疗。此外，随着专利到期和通用替代品的出现，医疗保健系统和保险公司通常会优先考虑具有成本效益的选择，从而激增需求。此外，阿维A的既定功效和安全性鼓励寻求可靠治疗牛皮癣及相关疾病的医疗保健提供者采用它。

到 2032 年，鱼鳞病细分市场将获得显着的市场份额，因为阿维A在治疗这种以干燥、鳞状皮肤为特征的罕见遗传性皮肤病方面已被证明有效。药物能够解决鱼鳞病的根本原因，加上其相对稀有性，使阿维A成为一种有价值的治疗选择，特别是在皮肤科护理的这一专业领域中推动了其需求。

到 2032 年，北美阿维A市场将占据重要的收入份额，原因是牛皮癣和相关皮肤病的流行，促使对有效治疗的强劲需求。医疗保健基础设施的进步和对皮肤科 RampD 的高度重视有助于提高治疗的认识和可近性。此外，患者权益团体和医疗保健提供者努力促进慢性皮肤病的有效管理策略，推动了阿维A在北美的采用，反映出其在皮肤病护理中日益重要的地位。

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

Amneal Pharmaceuticals, Inc.
Biophore.
Chongqing Huapont Pharmaceutical Co., Ltd.
Globe International Limited
GSK Plc
Merck KGaA
Prasco Laboratories
SGPharma Pvt Ltd
Sionc Pharmaceuticals Pvt. Ltd.
Sun Pharma Industries Limited

简介目录

Product Code: 9236

Global Acitretin Market will indicate over 4.6% CAGR between 2024 and 2032, backed by booming pharmaceutical and healthcare infrastructure. According to Invest India reports, the pharmaceutical industry of India will hit USD 65 billion by 2024 and double to USD 130 billion by 2030. It supplies 60% of global vaccine production, meeting 70% of WHOs DPT and BCG vaccine demand, and 90% of measles vaccine demand. Acitretins adoption in clinical practice is catapulted by its proven clinical effectiveness and established safety profile in managing severe psoriasis.

Healthcare providers prefer treatments that offer reliable outcomes with minimal adverse effects, making acitretin a preferred choice. Its efficacy in controlling psoriasis symptoms like scaling, inflammation, and plaque formation enhances patient satisfaction and compliance. Moreover, the drugs safety profile supports long-term use, further bolstering its appeal among clinicians.

The overall acitretin industry is sorted based on product type, dosage strength, application, distribution channel, end-use, and region.

The generics segment will imply a notable CAGR during the forecast period. Generic versions of Acitretin offer cost-effective alternatives to branded medications, making treatment more accessible to a broader patient population. Additionally, as patents expire and generic alternatives become available, healthcare systems and insurers often prioritize cost-efficient options, catapulting demand. Moreover, the established efficacy and safety profile of acitretin encourages its adoption among healthcare providers seeking reliable treatments for psoriasis and related conditions.

The ichthyosis segment will procure a noticeable market share by 2032, because of the proven efficacy of acitretin in managing this rare genetic skin disorder characterized by dry, scaly skin. The medications ability to address the underlying causes of ichthyosis, coupled with its relative rarity, positions acitretin as a valuable therapeutic option, driving its demand specifically within this specialized segment of dermatological care.

North America acitretin market will hold a significant revenue share by 2032, attribute to the prevalence of psoriasis and related skin disorders, prompting a robust demand for effective treatments. Advancements in healthcare infrastructure and a strong emphasis on dermatological R&D contribute to increased awareness and accessibility of treatments. Moreover, patient advocacy groups and healthcare providers efforts to promote effective management strategies for chronic skin conditions usher the adoption of acitretin in North America, reflecting its growing importance in dermatological care.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.2 Rising prevalence of psoriasis
- 3.2.3 Advancements in treatment
- 3.2.4 Growing awareness and diagnosis
- 3.2.5 Industry pitfalls & challenges
- 3.2.6 Stringent regulatory requirements
- 3.2.7 Side effects and safety concerns
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Branded
5.3 Generics

Chapter 6 Market Estimates and Forecast, By Dosage Strength, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2. 10mg
6.3. 25mg
6.4. 50mg

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Psoriasis
7.3 Ichthyosis
7.4 Darier disease
7.5 Pityriasis rubra pilaris
7.6 Solid organ transplants
7.7 Grover's disease
7.8 Lichen planus
7.9 Lupus erythematosus

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa